According to the top vaccine researcher at the US Walter Reed Army Institute of Research, scientists at the institute expect to know in the next few days if there's a concern that the COVID-19 vaccines might not work against a mutated variant of the virus that's rapidly spreading in parts of England, CNN reported on Monday.
Dr Nelson Michael, director of the Centre for Infectious Diseases Research at the Walter Reed Army Institute of Research, said that the Walter Reed scientists still expect the COVID-19 vaccine will be effective against this new virus variant.
Reportedly, on 17 December 2020, the Walter Reed team started examining genetic sequences of the new UK variant posted online by British researchers, with a computer analysis being done as a first step.
Michael said: "The computer analysis will allow us to gauge how much concern we should have", adding, "Other teams around the world are doing this analysis, too."
If the computer analysis shows there's a concern, then studies would need to be done in the laboratory and in animals to more definitively determine if the vaccine will work on this variant, CNN added.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial